Regeneron Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Regeneron Pharmaceuticals has a total shareholder equity of $26.0B and total debt of $2.0B, which brings its debt-to-equity ratio to 7.6%. Its total assets and total liabilities are $33.1B and $7.1B respectively. Regeneron Pharmaceuticals's EBIT is $4.2B making its interest coverage ratio -10. It has cash and short-term investments of $10.8B.
Key information
7.6%
Debt to equity ratio
US$1.98b
Debt
Interest coverage ratio | -10x |
Cash | US$10.84b |
Equity | US$25.97b |
Total liabilities | US$7.11b |
Total assets | US$33.08b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0R2M's short term assets ($19.5B) exceed its short term liabilities ($3.4B).
Long Term Liabilities: 0R2M's short term assets ($19.5B) exceed its long term liabilities ($3.7B).
Debt to Equity History and Analysis
Debt Level: 0R2M has more cash than its total debt.
Reducing Debt: 0R2M's debt to equity ratio has increased from 0% to 7.6% over the past 5 years.
Debt Coverage: 0R2M's debt is well covered by operating cash flow (231.7%).
Interest Coverage: 0R2M earns more interest than it pays, so coverage of interest payments is not a concern.